QQQ   440.36 (+0.31%)
AAPL   179.58 (-0.65%)
MSFT   412.46 (-0.29%)
META   500.00 (+2.01%)
GOOGL   138.00 (-0.33%)
AMZN   176.74 (-0.01%)
TSLA   199.48 (-1.19%)
NVDA   801.76 (+1.34%)
NIO   5.71 (-0.70%)
AMD   195.87 (+1.73%)
BABA   74.82 (+1.07%)
T   16.95 (+0.12%)
F   12.48 (+0.32%)
MU   93.72 (+3.43%)
CGC   3.22 (-2.13%)
GE   158.22 (+0.85%)
DIS   111.40 (-0.16%)
AMC   4.34 (+0.46%)
PFE   26.69 (+0.49%)
PYPL   60.57 (+0.38%)
XOM   106.09 (+1.50%)
QQQ   440.36 (+0.31%)
AAPL   179.58 (-0.65%)
MSFT   412.46 (-0.29%)
META   500.00 (+2.01%)
GOOGL   138.00 (-0.33%)
AMZN   176.74 (-0.01%)
TSLA   199.48 (-1.19%)
NVDA   801.76 (+1.34%)
NIO   5.71 (-0.70%)
AMD   195.87 (+1.73%)
BABA   74.82 (+1.07%)
T   16.95 (+0.12%)
F   12.48 (+0.32%)
MU   93.72 (+3.43%)
CGC   3.22 (-2.13%)
GE   158.22 (+0.85%)
DIS   111.40 (-0.16%)
AMC   4.34 (+0.46%)
PFE   26.69 (+0.49%)
PYPL   60.57 (+0.38%)
XOM   106.09 (+1.50%)
QQQ   440.36 (+0.31%)
AAPL   179.58 (-0.65%)
MSFT   412.46 (-0.29%)
META   500.00 (+2.01%)
GOOGL   138.00 (-0.33%)
AMZN   176.74 (-0.01%)
TSLA   199.48 (-1.19%)
NVDA   801.76 (+1.34%)
NIO   5.71 (-0.70%)
AMD   195.87 (+1.73%)
BABA   74.82 (+1.07%)
T   16.95 (+0.12%)
F   12.48 (+0.32%)
MU   93.72 (+3.43%)
CGC   3.22 (-2.13%)
GE   158.22 (+0.85%)
DIS   111.40 (-0.16%)
AMC   4.34 (+0.46%)
PFE   26.69 (+0.49%)
PYPL   60.57 (+0.38%)
XOM   106.09 (+1.50%)
QQQ   440.36 (+0.31%)
AAPL   179.58 (-0.65%)
MSFT   412.46 (-0.29%)
META   500.00 (+2.01%)
GOOGL   138.00 (-0.33%)
AMZN   176.74 (-0.01%)
TSLA   199.48 (-1.19%)
NVDA   801.76 (+1.34%)
NIO   5.71 (-0.70%)
AMD   195.87 (+1.73%)
BABA   74.82 (+1.07%)
T   16.95 (+0.12%)
F   12.48 (+0.32%)
MU   93.72 (+3.43%)
CGC   3.22 (-2.13%)
GE   158.22 (+0.85%)
DIS   111.40 (-0.16%)
AMC   4.34 (+0.46%)
PFE   26.69 (+0.49%)
PYPL   60.57 (+0.38%)
XOM   106.09 (+1.50%)
NASDAQ:SABS

SAB Biotherapeutics (SABS) Stock Price, News & Analysis

$4.51
+0.05 (+1.12%)
(As of 09:48 AM ET)
Today's Range
$4.50
$4.51
50-Day Range
$0.65
$6.22
52-Week Range
$3.66
$14.50
Volume
1,531 shs
Average Volume
16,355 shs
Market Capitalization
$23.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

SAB Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
121.7% Upside
$10.00 Price Target
Short Interest
Healthy
0.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of SAB Biotherapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$1,531 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($4.64) to ($2.96) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.01 out of 5 stars

Medical Sector

423rd out of 957 stocks

Biological Products, Except Diagnostic Industry

68th out of 160 stocks


SABS stock logo

About SAB Biotherapeutics Stock (NASDAQ:SABS)

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.

SABS Stock Price History

SABS Stock News Headlines

Bezos and Gates Invest in Search for Tech's Best-Kept Secret
Billionaires who've made their fortunes in tech, are quietly investing in essential yet rare elements known as "The Seeds of Technology". Learn more about this massive rare earth treasure hunt and the very elements making emerging technologies possible.
SAB Biotherapeutics Names Samuel Reich Chief Executive
SAB Biotherapeutics' Executive Chairman Reich Takes On Addl. Role As CEO
SAB Biotherapeutics Announces Executive Leadership Change
Bezos and Gates Invest in Search for Tech's Best-Kept Secret
Billionaires who've made their fortunes in tech, are quietly investing in essential yet rare elements known as "The Seeds of Technology". Learn more about this massive rare earth treasure hunt and the very elements making emerging technologies possible.
SAB Biotherapeutics GAAP EPS of -$0.10
See More Headlines
Receive SABS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/21/2023
Today
3/01/2024
Next Earnings (Estimated)
3/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SABS
Fax
N/A
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+124.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-18,740,000.00
Net Margins
-664.68%
Pretax Margin
-664.04%

Debt

Sales & Book Value

Annual Sales
$23.90 million
Book Value
$7.22 per share

Miscellaneous

Free Float
3,874,000
Market Cap
$23.33 million
Optionable
Not Optionable
Beta
0.90
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Samuel J. Reich (Age 49)
    CEO & Executive Chairman
    Comp: $376.2k
  • Dr. Eddie Joe Sullivan Ph.D. (Age 57)
    Co-Founder, President & Director
    Comp: $430.62k
  • Ms. Christine E. Hamilton M.B.A. (Age 68)
    Co-Founder & Independent Director
    Comp: $25k
  • Dr. Alexandra Kropotova M.B.A. (Age 51)
    M.D., Executive VP & Chief Medical Officer
    Comp: $486.96k
  • Dr. Edward D. Hamilton D.V.M.
    Co-Founder & Board Observer
  • Mr. Michael George King Jr. (Age 63)
    EVP & CFO
  • Dr. Christoph Bausch M.B.A. (Age 53)
    Ph.D., Executive VP & COO
  • Dr. Carlos N. Carillo Ph.D.
    Senior Vice President of Regulatory Affairs














SABS Stock Analysis - Frequently Asked Questions

Should I buy or sell SAB Biotherapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SAB Biotherapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SABS shares.
View SABS analyst ratings
or view top-rated stocks.

What is SAB Biotherapeutics' stock price target for 2024?

2 Wall Street research analysts have issued 12 month target prices for SAB Biotherapeutics' stock. Their SABS share price targets range from $10.00 to $10.00. On average, they expect the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 121.7% from the stock's current price.
View analysts price targets for SABS
or view top-rated stocks among Wall Street analysts.

How have SABS shares performed in 2024?

SAB Biotherapeutics' stock was trading at $0.6875 at the beginning of 2024. Since then, SABS stock has increased by 556.0% and is now trading at $4.51.
View the best growth stocks for 2024 here
.

When is SAB Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our SABS earnings forecast
.

How were SAB Biotherapeutics' earnings last quarter?

SAB Biotherapeutics, Inc. (NASDAQ:SABS) released its quarterly earnings results on Monday, August, 21st. The company reported ($0.14) earnings per share for the quarter, meeting the consensus estimate of ($0.14). The company had revenue of $0.09 million for the quarter. SAB Biotherapeutics had a negative trailing twelve-month return on equity of 120.36% and a negative net margin of 664.68%.

Who are SAB Biotherapeutics' major shareholders?

SAB Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include RTW Investments LP (175.49%), BVF Inc. IL (175.43%), Commodore Capital LP (35.02%), Vanguard Group Inc. (19.04%), Pathstone Holdings LLC (9.68%) and Kestra Advisory Services LLC (1.68%). Insiders that own company stock include Christine E Hamilton, Eddie Joe Sullivan, Michael King and Samuel J Reich.
View institutional ownership trends
.

How do I buy shares of SAB Biotherapeutics?

Shares of SABS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SABS) was last updated on 3/1/2024 by MarketBeat.com Staff